| 2019-07-09 08:04:02|
TROV 08:04 07/09 07/09/19
Trovagene begins enrollment of Phase 1b/2 study of onvansertib
Trovagene announced the initiation of patient enrollment of its Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin, or bevacizumab, for second-line treatment of patients with metastatic colorectal cancer, or mCRC, with a KRAS mutation, or NCT03829410. Trovagene is developing onvansertib, a first-in-class, third-generation, oral and highly-selective Polo-like Kinase 1 inhibitor that targets the key master regulator of tumor cell division, for the treatment of leukemias, lymphomas and solid tumor cancers. The trial is being conducted at USC Norris Comprehensive Cancer Center, Hoag Cancer Center and The Mayo Clinic, under the leadership of recognized colorectal cancer key opinion leaders.